Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
25 März 2022 - 07:07PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2022
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Director/PDMR Shareholding
25
March 2022 15:30 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca
PLC (the Company) announced that, on 24 March 2022, an award of the
Company's ordinary shares of $0.25 each (Ordinary Shares) vested to
Pascal Soriot, Executive Director and Chief Executive Officer,
under the terms of the AstraZeneca Performance Share Plan
(AZPSP).
The
AZPSP award was granted on 24 March 2017 and was subject to a
three-year performance period. On the third anniversary of grant
the award was placed in a two-year holding period. The award vested
at the end of that holding period. Application of the performance
measures specified at the time of grant resulted in 97% of the
AZPSP award vesting and the remaining unvested part
lapsing.
Following
the reinvestment of dividends accrued during performance and
holding periods of the AZPSP award, and the withholding of shares
to satisfy certain tax obligations arising on vesting, Mr Soriot's
beneficial interests in Ordinary Shares changed as detailed in the
table below:
|
PDMR
|
Ordinary
Shares acquired under the AZPSP
|
|
Pascal
Soriot
|
129,784
|
For
tax purposes, the fair market value of an Ordinary Share at vest of
the AZPSP award was 9,730 pence, being the closing price on the
last trading day preceding the vesting.
Further
details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Pascal
Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief
Executive Officer
|
|
b)
|
Initial
notification /Amendment
|
Initial
notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca
PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification
code
|
Ordinary
Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature
of the transaction
|
Acquisition of
ordinary shares pursuant to a vesting under the AstraZeneca
Performance Share Plan, for nil consideration.
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
129,784
|
|
d)
|
Aggregated
information
-
Aggregated volume
-
Price
|
Not
applicable - single transaction
|
|
e)
|
Date
of the transaction
|
24
March 2022
|
|
f)
|
Place
of the transaction
|
Outside
a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
25 March 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2022 bis Jun 2022
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2021 bis Jun 2022
